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Abstract
Background: Although methylation-mediated inactivation of expression of RASSF1A, a candidate
tumor suppressor gene, has been observed in several human cancers, the data concerning
alteration of RASSF1A expression and methylation in Chinese primary gastric cancer are scarce.
Moreover, direct evidence showing the association between protein expression of RASSF1A and
primary human cancers is lacking. The aim of this study was to investigate RASSF1A expression in
tissue of primary gastric cancer (GC) at mRNA and protein levels, and to establish the possible
relationship between DNA methylation status and protein expression of RASSF1A in Chinese.
Methods: Fifty-four patients with primary gastric cancers were included in the study of RASSF1A
mRNA expression and methylation status between the cancer tissue and the corresponding
adjacent normal tissue. 20 out of 54 patients were included for study of RASSF1A protein
expression. The expression of RASSF1A at mRNA and protein levels was determined by RT-PCR
and Western-blotting, respectively. The RASSF1A promoter methylation was detected by
methylation-specific PCR.
Results:  RASSF1A mRNA and protein expressions in GC were reduced significantly with
comparison to the corresponding normal tissues (OD value: 0.2589 ± 0.2407 vs 0.5448 ± 0.2971,
P < 0.0001; 0.1874 ± 0.0737 vs 0.6654 ± 0.2201, P < 0.0001, respectively). Methylation frequency
of RASSF1A in primary GC is higher than that in the corresponding normal tissues (66.7% vs. 14.8%,
P < 0.0001). Furthermore, RASSF1A mRNA expression in methylation group of GC was further
reduced when compared to the unmethylation group of GC (0.1384 ± 0.1142 vs. 0.5018 ± 0.2463,
P < 0.0001).
Conclusion: Expression of RASSF1A was reduced in tissue of GC at mRNA and protein levels.
Diminished expression of RASSF1A was associated with the promoter methylation.
Background
Gastric cancer (GC) is one of the most common malig-
nancies in gastrointestinal diseases. Although incidence of
GC is declining in the developed counties, it is still a lead-
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ing cause of death from cancers in most developing coun-
tries. Both genetic and environmental factors including H.
pylori infection have been considered to contribute to the
development of GC. Recently, several studies have shown
that silence of tumor suppressor genes by epigenetic mod-
ification is a fundamental mechanism for inactivation of
cancer-related genes in the pathogenesis of human cancer
[1]. Of the particular note is the fact that promoter hyper-
methylation plays an essential role in the loss of function
of tumor suppressor genes.
Allelic loss at chromosome 3p21.3 is one of the most fre-
quent genetic changes in various types of human cancers
[2]. In the late 90's, Dammann [3] and Burbee [4] et al
identified RASSF1A, a novel gene from the common
homozygous deletion area at 3p21.3. This gene shares
homology with mammalian RAS effectors. There are
seven RASSF1 isoforms (A to G) generated through alter-
native splicing RASSF1A has been shown to reduce tumor-
igenicity in vivo and is frequently inactivated in a variety
of primary human cancers. Genetic mutations in this iso-
form are rare. It is known that epigenetic silencing of
RASSF1A associates with CpG islands methylation of the
promoter region. Bisulfate DNA sequencing has demon-
strated that hypermethylation of promoter region inacti-
vates RASSF1A expression in the major human cancers.
This is supported by the observation of re-expression of
RASSF1A in various cancer cell lines treated with demeth-
ylating agents [4-7]. To date, several studies have shown
the presence of aberrant promoter methylation of
RASSF1A and loss or abnormal low expression of
RASSF1A in primary GC, suggesting that inactivation of
RASSF1A expression is closely associated with the pro-
moter methylation [5,8-10]. To our best knowledge, no
data concerning the expression of RASSF1A and methyla-
tion status in GC in Chinese population are available. In
the present study, we have determined expression of
RASSF1A at both mRNA and protein levels, and their asso-
ciation with RASSF1A promote methylation status in Chi-
nese primary GC in the central China.
Methods
Patients
Fifty-four patients with primary GC were registered in the
Wuhan University Zhongnan Hospital and the Hubei Pro-
vincial Cancer Hospital from December 2003 to June
2005, and all of the patients underwent curative resection
with systematic lymph node dissection. GC tissues and
corresponding adjacent normal gastric tissues were
obtained from operations before chemotherapy. The
patients included 35 males and 19 females, mean age 57.6
± 13.7 years (range from 30 to 85 years). Diagnosis and
differentiations of GC were determined by histopatholog-
ical examinations and the TNM classification. The demo-
graphic and clinicopathological data of the patients are
summarized in Table 1. Among 54 patients with GC, 20
cases were included for study of protein expression of
RASSF1A. The protocol of the study was approved by the
ethic committee of Wuhan University Zhongnan Hospi-
tal. Tumor and adjacent normal tissues were obtained at
the time of surgery, snap-frozen in liquid N2 and stored at
-80°C until used. Sample sections were stained in H&E
and were examined by two experienced pathologists.
DNA and RNA extract
DNA from frozen tissues was purified by phenol/chloro-
form and ethanol precipitation and dissolved in 50 μl of
distilled water and stored at -20°C until use. Total RNA
was isolated using the Trizol kits (Molecular Research
Center Inc., Cincinnati, USA) according to the manufac-
turer's instruction.
Semi-quantitative RT-PCR
Three micrograms of total RNA were reversely transcribed
using RevertAid™ first strand cDNA synthesis kit (Fermen-
tas Inc., Vilnius, Lithuania). All total RNA were treated by
DNase to avoid contamination of genomic DNA. The
primers for RASSF1A and glyceraldehydes-3-phosphate
dehydrogenase (GAPDH) were designed based on
RASSF1A gene (GeneBank Accession #: NM_007182) and
GAPDH gene (GeneBank Accession #: NM_002046). The
primers for RASSF1A were 5'-CTT TTA CCT GCC CAA
GGA TGC-3' and 5'-CAC CTC CCC AGA GTC ATT TTC C-
3'. The primers for GAPDH (5'-CAT GAC AAC TTT GGT
ATC GTG-3', and 5'-GTG TCG CTG TTG AAG TCG TCA
GA-3') were used as internal control. The thermal cycles
were: 94°C for 5min, followed by 35 cycles of 94°C for
30sec, 55°C for 45sec and 72°C for 60sec, and finally
72°C for 5min for extension. The PCR products were sep-
arated in 2% agarose gel in electrophoresis and visualized
with ethidium bromide staining, and quantified using an
image analysis system (UVP Bioimaing systems, USA).
The generated PCR products were 265bp for RASSF1A and
370 bp for GAPDH. Optical density (OD) value of the
mRNA expression was calculated.
Bisulfate modification
DNA from tumor tissues and corresponding adjacent nor-
mal tissues were subjected to bisulfate treatment accord-
ing to Herman et al [11]. Briefly, 2 μg of genomic DNA
suspended in 50 μl distilled water, denatured with 0.2 M
NaOH for 10 min at 37°C, and added 30 μl of freshly pre-
pared 3 M sodium bisulfate (pH 5.0). The samples were
over layered with mineral oil to cover surface of the aque-
ous phase, and incubated at 50°C for 16~20 h. The DNA
sample was desalted through a column of Wizard DNA
Clean-up System (Promega, Wisconsin, USA) according
to the manufacturer's instructions. The samples were
treated with 0.3 M NaOH for 5 min at room temperature
and precipitated with ethanol. The bisulfate-modifiedBMC Cancer 2007, 7:120 http://www.biomedcentral.com/1471-2407/7/120
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genomic DNA was re-suspended in 50 μl TE buffer (10
mM Tris·Cl, 1 mM EDTA, pH7.6) and stored at -80°C for
use.
Methylation-specific PCR (MSP)
The methylation status of RASSF1A was determined by
MSP. Bisulfate treatment of genomic DNA converts cyto-
sine to uracil bases but has no effect on methylcytosine.
The specific PCR was then used to distinguish between
methylated and unmethylated DNA sequences in a Hot-
Star TaqE PCR machine (TaKaRa Bio, Co., Ltd., Tokyo,
Japan). The primers for the methylated form were 5'-GGG
TTT TGC GAG AGC GCG-3' and 5'-GAT AAC AAA CGC
GAA CCG-3', and the primers for the unmethylated form
were 5'-GGG GTT TTG TGA GAG TGTG-3' and 5'-ACT
AAC AAA CAC AAA CCA AAC-3' (Gene Bank Accession:
AC002481). The PCR condition consisted of one incuba-
tion of 15 min at 95°C, followed by 40 cycles of a 30 sec
denaturation at 94°C, 50 sec at an annealing temperature
(64°C for methylated and 59°C for unmethylated specific
primers), and a 30 sec extension at 72°C, and a final
extension at 72°C for 10 min. PCR products were sepa-
rated in 8% polyacrylamide gels in electrophoresis.
Genomic DNA, methylated in vitro by CpG methyltrans-
ferase (Sss I) following the manufacturer's directions
(New England BioLabs, Inc., Beverly, MA), was used as a
positive control. Water blank was used as a negative con-
trol. Each primer set generated a 169 bp product.
Western blotting
Fifty mg samples were homogenized and centrifuged at
12,000–15,000 g for 10–15 min in ice-cold 50 mM
HEPES buffer (pH 7.4) containing 150 mM NaCl, 50 mM
Tris·Cl (pH 8.0), 1% Triton X-100, 2 mM EDTA, 2 mM
PMSF, 5 μg/ml leupeptin, 1% NP-40, and 10% glycerol.
Supernate was collected and protein concentration was
then measured using BSA as a standard by the BCA Pro-
tein Assay Reagent (Pierce Biotechnology., Inc., Rockford,
USA). Equal amounts (100 μg) of total protein from tis-
sues were electrophoresed on SDS-polyacrylamide gels
(10% gel) and transferred to polyvinylidine difluoride
(PVDF) filter membranes for 30 min bysemi-dry blotting.
The membranes were blocked for 2 h at room temperature
with the block solution provided in the ECL kit (Protein
Detector LumiGLO Reserve™ Western Blotting Kit, KPL,
Maryland, USA), and then incubated for 45 min with a
1:100 dilution of the primary antibody to RASSF1A. The
primary antibody used for Western blot analysis was an
affinity purified goat polyclonal antibody to RASSF1A, C-
12 (SC-18724, Santa Cruz Biotechnology Inc., Santa Cruz,
Calif., USA). The PVDF membranes were then washed for
30 min using a wash solution, followed by an 1 h incuba-
Table 1: Association of RASSF1A gene methylation with demographics and clinicopathological features of primary gastric cancer (n = 
54)
Methylation P value OR (95%CI)
Yes No
Gender
male 24 11 0.766 1.273 (0.393~4.117)
female 12 7
Age
< 60 17 13 0.145 0.344 (0.101~1.167)
≥ 60 19 5
Tumor sites
antrum 14 7
body and cardiac 22 11 1.000 1.000 (0.313~3.192)
Stages
early 1 2 0.255 0.229 (0.019~2.708)
advanced 35 16
Lymph node metastasis
yes 22 7 0.154 2.469 (0.774~7.882)
no 14 11
Distant metastasis
yes 5 1 0.651 2.742 (0.296~25.424)
no 31 17
Differentiations
well and moderate 18 12 0.384 0.500 (0.154~1.624)
poor 18 6
Lauren's
Intestinal type 12 10 0.148 0.400(0.125~1.275)
Diffuse type 24 8BMC Cancer 2007, 7:120 http://www.biomedcentral.com/1471-2407/7/120
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tion with anti-goat antibody conjugated to horseradish
peroxidase in block solution (Rabbit anti-goat IgG,
Chemicon Internation, Inc., Temecula, California, USA).
ThePVDF membranes were washed again and the immu-
noreactive bands were detected by enhanced chemilumi-
nescence and visualized by image analysis system (Bio-
Rad Laboratories, Inc. Hercules, CA, USA). GAPDH
(Abcam Biotechnology, Cambridge, UK) was used as con-
trol.
Statistical analysis
Statistical analyses were performed using the SPSS11.5
software (SPSS, Inc., Chicago, IL). The differences
between the variables were assessed by chi square test or t-
tests according to the data. The statistical significance of
differences was set as P < 0.05.
Results
RASSF1A mRNA expression in gastric cancer
RASSF1A mRNA expression in 54 GC tissues was 50% of
that in the adjacent corresponding normal tissues, which
revealed mRNA expression in tumors was significantly
reduced compared with that of the normal tissues as
shown in Fig. 1.
RASSF1A protein expression in gastric cancer
Consistent to the decrease in mRNA expression, figure 2
shows that the protein expression in tumors was only
21.4% of that in normal tissues, which suggested that the
protein level of RASSF1A expression was also reduced
with comparison to the corresponding normal tissues.
RASSF1A mRNA expression and DNA methylation in 
promoter of RASSF1A gene in primary gastric cancer
As shown in Fig. 3, methylation frequency of RASSF1A in
GC was 3.5-fold higher than that in the corresponding
normal tissues (66.7% vs 14.8%, P < 0.0001). RASSF1A
mRNA expression between methylation and unmethyla-
tion groups in GC were significantly different, the former
is 2.6-fold lower than the latter (0.1384 ± 0.1142 vs
0.5018 ± 0.2463, P < 0.0001). The results showed that
hypermethylation at the CpG island in the RASSF1A pro-
moter is strongly associated with significantly reduced
mRNA expression of RASSF1A.
Association between methylation and clinicopathological 
parameters of gastric cancer
The association between promoter methylation and rele-
vant demographic and clinicopathological characteristics
including gender, age, tumor site, lymph node metastasis,
distant metastasis, differentiation, stage and Lauren's type
were shown in Table 1. There was no significant associa-
tion between promoter methylation and the clinicopatho-
logical parameters.
Protein expression of RASSF1A in primary gastric cancer (T)  and corresponding normal tissue (N) Figure 2
Protein expression of RASSF1A in primary gastric cancer (T) 
and corresponding normal tissue (N). Protein level of 
RASSF1A was quantified by Western-blotting compared with 
GAPDH.
Expression of RAASF1A mRNA in primary gastric cancer (T)  and corresponding normal tissue (N) Figure 1
Expression of RAASF1A mRNA in primary gastric cancer (T) 
and corresponding normal tissue (N). RT-PCR products for 
RASSF1A were quantified by densitometric scanning of in 
ethidium bromide-stained gels compared with GAPDH.BMC Cancer 2007, 7:120 http://www.biomedcentral.com/1471-2407/7/120
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Discussion
In the present study we provided evidence that RASSF1A
expression in GC was reduced at mRNA and protein levels
and the methylation in promoter region of the RASSF1A
gene was 3.5-fold more frequent in primary GC than in
corresponding normal tissues. In addition, the incidence
of GC patients with RASSF1A promoter methylated over
unmethylated was 2-fold higher. These suggest that
RASSF1A expression in GC was highly associated with the
promoter methylation status of the RASSF1A gene. To fur-
ther confirm the relationship between expression of
RASSF1A and the methylation of the promoter, we com-
pared RASSF1A mRNA expression between methylation
and unmethylation tissues in GC, and found that aberrant
methylation of the RASSF1A gene promoter region is
responsible for the reduction or loss of RASSF1A mRNA
expression in primary GC. Our study was consistent with
one study which showed that 45.6% primary GC had
none or abnormally low mRNA expression of RASSF1A
[5]. Among 30 matched sets from the same patients
73.3% of GC was found to have reduced RASSF1A expres-
sion [5]. To our best knowledge, no study of RASSF1A
protein expression in GC has been reported. We further
analyzed RASSF1A expression at protein level by Western
blotting in 20 GC patients and found that the protein
expression in tumors is only 21.4% of the expression in
normal tissues. This result indicated that RASSF1A protein
expression in GC was significantly lower than in corre-
sponding adjacent normal tissues. This is consistent to the
mRNA expression of RASSF1A.
The mechanism of reduced or silenced RASSF1A expres-
sion could be caused by promoter methylation and/or
mutation of RASSF1A gene. However, several studies have
shown that mutation of RASSF1A gene is very rare
[4,5,7,12,13]. Thus, RASSF1A gene is probably inactivated
by mechanisms of methyltion. Byun et al [5] found that of
41 primary GC with loss or abnormal reduction of
RASSF1A expression, 39 were methylated, whereas in
both GC and normal tissues with normal RASSF1A
expression none were methylated. To et al[10] showed
that hypermethylation of RASSF1A promoter was found
in 25.8% of GC and in 11.1% of the gastric intestinal
metaplasia(IM), respectively. Our data has shown that the
frequency of RASSF1A methylation in GC was higher than
the above reported data. GC is highly prevalent in China
and high methylation of RASSF1A may explain partly the
reason for why GC incidence is higher in the Chinese.
Interestingly, the fact that RASSF1A promoter hypermeth-
ylation is higher in EBV positive GC than in EBV negative
carcinoma (66.7% vs 3.6%) may suggest a close associa-
tion between EBV and aberrant methylation in GC.
Indeed, a previous report has indicated that viral oncogen-
esis might involve aberrant methylation, resulting in inac-
tivation of tumor suppressor genes [9].
We found that the methylation frequency of RASSF1A in
primary GC and in the corresponding normal tissues were
66.7% and 14.8%, respectively. Our data showed that out
of 54 GC patients 36 were methylated and 18 were
unmethylated, suggesting methylated GC is more com-
mon, in agreement with the other reports. The previous
study [14] suggested that the stomach is one of the normal
tissues with a high frequency of aging-related methyla-
tion, and gastric cancer is one of the tumors with a high
frequency of CpG island methylation. Kang et al [15]
studied the methylation status of 11 genes in nonneoplas-
tic gastric mucosa and they found that aberrant CpG
island methylation occurred frequently in chronic gastri-
tis, which showed aging relationship, and that aging-
Methylation of RASSFIA in primary gastric cancer and corresponding normal tissue by MSP Figure 3
Methylation of RASSFIA in primary gastric cancer and corresponding normal tissue by MSP. Lane 3, 4 and lane 6, 7 show a rep-
resentative result from a tumor and normal sample, respectively. U: amplified product with primer recognizing unmethylated 
sequences; M: amplified product with primer recognizing methylated sequences. Genomic DNA, methylated in vitro by CpG 
methylase (Sss I) was used as a positive control. Water blank was used as a negative control. The PCR products were resolved 
on a 8% polyacrylamide gelsBMC Cancer 2007, 7:120 http://www.biomedcentral.com/1471-2407/7/120
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related methylation was gene type-specific. RASSF1A gene
was rarely methylated, with no aging relationship. Fur-
thermore, other authors reported [3-5] that in normal tis-
sues, no methylated RASSF1A alleles were detected.
However, our data showed that in the corresponding nor-
mal tissues, the RASSF1A methylation frenquency was
high percentage (14.8%). The discrepancy between our
data and other authors' may be due to the difference of the
samples, which we studied were the non-nesoplasia gas-
tric tissues in patients with gastric cancer and it's very
likely to include chronic gastritis tissues, especially intes-
tinal metaplasia tissues in the corresponding adjacent
normal tissues. The previous study reported that several
genes were frequently methylated in chronic gastritis,
especially in intestinal metaplasia tissues. To et al [10]
examined the 8 tumor-related gene methylation status
including RASSF1A in gastric intestinal metaplasia in
patients with and without gastric cancer, and they found
that the frequency of methylation in RASSF1A in cancer
and intestinal metaplasia were 25.8% and 11.1%, respec-
tively. The result was consistent with ours. In fact, we
sequenced the MSP products for several samples. The
sequence was consistent to the sequence predicted (data
not show). We found that unmethylated bands always
coexist with methylated bands in most primary GC and
corresponding adjacent normal tissues in spite of reduc-
tion or loss of RASSF1A expression, consistent with previ-
ous reports [4,10]. This is most likely these resected
tumors were not microdissected and were contaminated
with stromal cells. Additionally, MSP is extremely sensi-
tive. Bai et al [16] thought that detection of these two
bands represents either intra-allelic heterogeneity of the
CpG island methylation or methylation of the island var-
ying from allele to allele. Alternatively, our result might
indicate that partial methylation of the RASSF1A gene
promoter is enough to silence the gene transcription since
loss of a single gene copy is sufficient to promote tumor
formation [17,18]. Tommasi et al [19] observed that het-
erozygous RASSF1A knockout mice were significantly
tumor-prone, both for spontaneous tumor formation and
for the chemically induced tumors. This may suggest that
the RASSF1A gene has the characteristics of conferring
haploinsufficiency when only one allele is lost.
We also investigate the association between promoter
hypermethylation and relevant clinicopathologic parame-
ters including age and gender of the patients, site of carci-
noma, histological differentiation, Lauren's type and
metastasis of GC. We found that frequency of the methyl-
ation of RASSF1A gene was markedly higher in advanced
tumors compared with early stage tumors(68.6% vs
33.3%), and higher in poorly differentiated tumors (75%
vs 60%) when compared with well and moderately differ-
entiated tumors. However, these differences don't reach
statistical significance. Byun et al [5] have shown that
inactivation of RASSF1A was correlated with tumor stage
and grade but not with histological types of tumors. The
discrepancy may explain by limited samples for early GC
in our study.
Transfection of RASSF1A gene reduces the growth of
human cancer cell in vitro and in vivo [3,4], supporting a
role for RASSF1A as a tumor suppressor gene. RASSF1A
activating RAS may require heterodimerization of
RASSF1A and the novel Ras effector (NORE1), and induce
apoptosis through its interaction with Ras, NORE1, the
connector enhancer of KSR (CNK) and the pro-apoptotic
MST1 kinase [20]. Several groups have reported that
RASSF1A is a microtubule-binding protein and regulates
mitotic progression [21-25], and may function in signal
transduction pathways involving RAS like small GTPase
proteins. Tommasi et al[19] has demonstrated that
Rassf1a-/- and Rassf1a +/- mice have increased tumor mul-
tiplicity and tumor size, suggesting further the role of
tumor suppression of RASSF1A, which may explain its fre-
quent epigenetic inactivation in human tumors.
Conclusion
In summary, the expression of RASSF1A was markedly
reduced to an abnormal level or completely lost in pri-
mary GC compared with adjacent normal tissue, and was
correlated to hypermethylation of the promoter of the
RASSF1A gene. Further work is necessary to elucidate its
exact function and interaction with other factors to
develop strategies for early diagnosis, prevention and
treatment of gastric cancer.
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